Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BMS-790052 added to Peginterferon Alfa-2a
and ribavirin can result in higher cure rates in patients who previously failed therapy and
may have limited response to retreatment with Peginterferon Alfa-2a and ribavirin alone.